Objective To explore the clinical efficacy of Xuesaitong combined with Argatroban in acute cerebral infarction. Methods From March 2020 to December 2021， 124 patients with acute cerebral infarction admitted to the Sixth People's Hospital of Hengshui were selected for subjects. Randomized numerical method was used to divide the patients into combined group （62 cases） and control group （62 cases）. Control group was given conventional treatment and Argatroban， and combined group was treated with Xuesaitong in addition to control group. National Institute of Health Stroke Scale （NIHSS） scores， cerebral circulation dynamics indices， soluble tumor necrosis factor-like weak inducer of apoptosis （sTWEAK） levels， overall efficiency， and adverse effect were compared between the two groups of patients before treatment and after 14 days of treatment. Results After 14 days of treatment， the overall efficiency of 90.32% （56/62） in combined group was higher than the overall efficiency of 70.97% （44/62） in control group， and the difference was statistically significant （χ2 =7.440， P＜ 0.05）. There was no statistically significant difference in NIHSS scores， minimum blood flow velocity （Vmin）， minimum blood flow （Qmin）， cerebrovascular resistance （R）， and sTWEAK levels between the two groups before treatment （all P＞ 0.05）. After treatment， NIHSS scores ［（4.21±1.02） vs. （6.98±1.21）］， R ［（1 802.50）±188.64） vs. （1 925.41±199.86） Pa·s/ml］， and sTWEAK levels ［（78.21±10.42） vs. （125.98±13.25）］ in combined group were lower than those in control group， and the levels of Vmin ［（10.51±1.73） vs. （9.25±1.64） cm/s］， and levels of Qmin ［（4.75±0.98） vs （4.26±0.95） ml/s］ were higher than those of control group， and the difference between the two groups before and after treatment was also statistically significant （all P＜ 0.05）. The difference in the total incidence of adverse reactions between the two groups was not statistically significant （P＞ 0.05）. Conclusions The efficacy of Xuesaitong combined with Argatroban for acute cerebral infarction is good， which can improve the patients' cerebral blood circulation status as well as the recovery of neurological function.